Syndax Pharmaceuticals offers convertible senior notes due 2031
Syndax Pharmaceuticals is issuing convertible senior notes due 2031 to accredited and institutional investors without SEC registration. The offering allows conversion into cash, common stock, or a combination thereof at the company's election.
View filing at SEC.gov →